TTM
26.9%
YoY change
+2.36pp
Trough year (2014)
18.0%
Peak year (2021)
42.6%
Latest annual
28.8%
EBITDA Margin history chart for AbbVie (ABBV) from 2009 to 2025
Latest: 28.8%
EBITDA Margin change chart for AbbVie (ABBV) from 2009 to 2025
Latest: +2.36pp
EBITDA Margin history table for AbbVie (ABBV) from 2009 to 2025
| 2025 | 28.8% | +2.36pp | ||
| 2024 | 26.5% | -5.15pp | ||
| 2023 | 31.6% | -10.03pp | ||
| 2022 | 41.6% | -0.95pp | ||
| 2021 | 42.6% | +15.68pp | ||
| 2020 | 26.9% | -9.85pp | ||
| 2019 | 36.8% | +11.38pp | ||
| 2018 | 25.4% | -11.41pp | ||
| 2017 | 36.8% | -2.69pp | ||
| 2016 | 39.5% | +3.60pp | ||
| 2015 | 35.9% | +17.92pp | ||
| 2014 | 18.0% | -16.79pp | ||
| 2013 | 34.7% | -3.23pp | ||
| 2012 | 38.0% | +9.65pp | ||
| 2011 | 28.3% | -10.18pp | ||
| 2010 | 38.5% | -2.30pp | ||
| 2009 | 40.8% | — |
- 202528.8%+2.36pp
- 202426.5%-5.15pp
- 202331.6%-10.03pp
- 202241.6%-0.95pp
- 202142.6%+15.68pp
- 202026.9%-9.85pp
- 201936.8%+11.38pp
- 201825.4%-11.41pp
- 201736.8%-2.69pp
- 201639.5%+3.60pp
- 201535.9%+17.92pp
- 201418.0%-16.79pp
- 201334.7%-3.23pp
- 201238.0%+9.65pp
- 201128.3%-10.18pp
- 201038.5%-2.30pp
- 200940.8%—
EBITDA Margin values are taken from AbbVie's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EBITDA Margin at AbbVie (ABBV)
According to AbbVie's latest reported financial statements, the company's latest reported EBITDA margin is 26.9%. EBITDA margin is EBITDA divided by revenue — earnings before interest, taxes, depreciation, and amortization as a percentage of sales. By stripping out non-cash charges and capital-structure effects, it approximates operating cash profitability and is widely used to compare companies with different asset bases and leverage.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
In 2025, AbbVie (ABBV) EBITDA margin totalled 28.82% – expanded 2.4 percentage points year-over-year.
Across the available history, EBITDA margin reached its high of 42.59% in 2021 and its low of 17.96% in 2014.
AbbVie EBITDA Margin by Year
AbbVie EBITDA Margin 2025: 28.8%
AbbVie posted EBITDA margin of 28.82% in 2025, expanded 2.4 percentage points from 2024.
AbbVie EBITDA Margin 2024: 26.5%
In 2024, AbbVie reported EBITDA margin of 26.47%, contracted 5.1 percentage points from 2023.
AbbVie EBITDA Margin 2023: 31.6%
AbbVie EBITDA margin in 2023 was 31.61%, contracted 10.0 percentage points from 2022.
AbbVie EBITDA Margin 2022: 41.6%
2022's EBITDA margin for AbbVie came in at 41.64%, contracted 0.9 percentage points from 2021.
AbbVie EBITDA Margin 2021: 42.6%
AbbVie EBITDA margin in 2021 was 42.59%.
See more financial history for AbbVie (ABBV).
Sector peers by EBITDA Margin
Healthcare peers of AbbVie (ABBV), ranked by their latest EBITDA margin
| 55.4% | |
| 46.6% | |
| 45.9% | |
| 34.6% | |
| 33.9% | |
| 30.3% | |
| 24.7% | |
| 5.1% |
- 55.4%
- 46.6%
- 45.9%
- 34.6%
- 33.9%
Frequently asked questions
AbbVie (ABBV) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation